Lilly investing $1.5 billion in new production facilities

29 January 2022

US pharma Eli Lilly (NYSE: LLY) saw its shares close up 3.5% at $245.10 on Friday, after it announced plans to significantly expand production facilities in the USA and Ireland.

As the number of people that can benefit from Lilly's innovative new medicines continues to increase, Lilly said it is expanding its manufacturing footprint with an investment of more than $1.5 billion in brand-new facilities in Concord, North Carolina. and Limerick, Ireland to help meet the demand.

Over the last eight years, Lilly delivered 16 new medicines and aims to introduce five potential new medicines in the next two years, the company noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK